These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22973719)

  • 1. A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.
    Mokuyasu S; Suzuki Y; Seto T; Miyachi H; Tokuda Y
    Rinsho Byori; 2012 Jul; 60(7):612-20. PubMed ID: 22973719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method.
    Kuroda N; Kontani K; Kajikawa T; Taminato T
    Rinsho Byori; 2010 Jun; 58(6):541-52. PubMed ID: 20662264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
    Witzel I; Loibl S; von Minckwitz G; Mundhenke C; Huober J; Hanusch C; Henschen S; Hauschild M; Lantzsch T; Tesch H; Latos K; Just M; Hilfrich J; Barinoff J; Eulenburg CZ; Roller M; Untch M; Müller V
    Breast Cancer Res Treat; 2010 Sep; 123(2):437-45. PubMed ID: 20623180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
    Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
    J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].
    Couto Mdo R; Pinto D; Oliveira J; Monteiro A; Pereira D; Medeiros R; Rodrigues H
    Acta Med Port; 2011; 24(1):5-16. PubMed ID: 21672436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
    Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
    PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
    Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.
    Garoufali A; Kyriakou F; Kountourakis P; Yioti I; Malliou S; Nikaki A; Kardara E; Frangos I; Koumna S; Baziotis N; Scorilas A; Ardavanis A
    J BUON; 2008; 13(3):409-13. PubMed ID: 18979558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer.
    Tsé C; Gauchez AS; Jacot W; Lamy PJ
    Cancer Treat Rev; 2012 Apr; 38(2):133-42. PubMed ID: 21549508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
    Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
    Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab.
    Stemmler HJ; Stieber P; Lässig D; Heinemann V
    Onkologie; 2005 Feb; 28(2):95-7. PubMed ID: 15692222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
    J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
    Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
    Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.